Home BioMarin's FDA Panel: Revisiting Biotech's Biggest Battle
 

Keywords :   


BioMarin's FDA Panel: Revisiting Biotech's Biggest Battle

2015-11-30 16:10:16| Biotech - Topix.net

BioMarin's exon-skipping drug, drisapersen, has occupied biotechnology investors' minds over the past week. is a debilitating muscular disease that affects boys less than 10 years of age and slowly causes progressive muscle wasting resulting in loss of walking ability, and respiratory and cardiac failure with 100% death rate within few years.

Tags: panel battle biggest fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11US jobs growth slows as presidential election looms
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Sky Glass now available to buy at Currys
01.11House sales forecast to 'jump' ahead of stamp duty rise
01.11X Games chooses frequency to power sports FAST channel
01.11U.S. video streaming hits ceiling in Q3 2024
01.11Roku releases third quarter 2024 financial results
More »